Sanofi ended development of Nurix’s STAT6 degrader, known as SAR448272, just as the target pathway was drawing analytical attention as a potential immunology pillar. The company said it will no longer pursue the program. The move highlights how even early clinical momentum can be reversed if data or therapeutic strategy alignment changes during development. For biotech partners and platform developers, the termination is a reminder that partnering does not insulate programs from strategic reprioritization once clinical and portfolio constraints tighten.